查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931223

婦科避孕植入市場（按產品、最終用戶和分銷管道分類），全球預測，2026-2032年

Gynecological Contraceptive Implant Market by Product, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，婦科避孕植入市場價值將達到 4.5094 億美元，到 2026 年將成長至 4.7552 億美元，到 2032 年將達到 6.5719 億美元，複合年成長率為 5.52%。

關鍵市場統計數據
基準年 2025 4.5094億美元
預計年份：2026年 4.7552億美元
預測年份 2032 6.5719億美元
複合年成長率 (%) 5.52%

綜合考慮避孕植入的臨床意義、相關人員的責任以及對護理路徑和病人歷程。

避孕植入已成為眾多生殖健康工具中的佼佼者，它經久耐用，由醫護人員操作，能夠持續釋放激素，並提供可預測的避孕效果。這些裝置擴大應用於計劃生育診所、全科診所、醫院以及青少年和婦女專科中心等臨床診療流程中，由此引發了一系列除了產品性能之外的運營和臨床考量，包括培訓、庫存管理和患者諮詢。

簡要概述臨床創新、數位醫療服務和政策調整如何整合，從而重新定義產品採用路徑和服務經濟。

避孕植入市場正受到臨床、技術和政策變革的共同影響，這些變革正在重新定義產品開發和服務提供方式。器械設計和荷爾蒙配方方面的進步，以及關於長期使用和懷孕復發率的新證據，促使臨床醫生和指南制定者重新評估諮詢框架和植入通訊協定。因此，臨床實踐正朝著更個人化的避孕方案轉變，這些方案會考慮患者的生命週期並兼顧其合併的疾病。

對 2025 年實施的關稅對整個植入供應鏈的採購、購買和服務成本的影響進行客觀分析。

美國2025年關稅政策對避孕植入物組件和成品引入了新的進口規定，對生產、分銷和採購管道產生了廣泛影響。這些關稅提高了從受影響地區採購的產品和原料的到岸成本，促使製造商評估替代採購方案並重新考慮其定價策略。因此，醫院、診所和專科醫療中心的採購團隊在評估植入項目的總擁有成本（TCO）時，面臨更嚴格的談判和審查。

基於細分市場的詳細分析，將營運影響與產品化學、臨床環境、通路以及按年齡層分類的患者優先事項聯繫起來

產品細分分析揭示了兩種主要植入化學成分在臨床和商業性的顯著差異。依托孕烯植入定位為長效避孕藥，具有成熟的醫護人員認知度和規範的追蹤通訊協定；而levonorgestrel植入則常用於需要其他激素組合且對成本敏感的採購場景。這些產品特性會影響臨床醫生的培訓需求、諮詢服務以及不同臨床環境下的庫存規劃。

區域比較分析：說明監管差異、衛生系統結構和區域准入優先事項如何影響全球植入交付。

區域趨勢正在以不同的方式影響美洲、歐洲、中東和非洲以及亞太地區的監管流程、支付方參與和服務提供結構。在美洲，綜合醫療系統和大規模私人醫療服務網路推動了密集的採購週期和集中式培訓項目，而該地區多樣化的公共衛生舉措則側重於擴大服務覆蓋範圍和分擔任務，以提高避孕藥具的可及性。

策略性企業因應措施和競爭定位的核心在於：優先考慮臨床證據、拓展通路，並透過強大的供應鏈體系促進產品的廣泛應用。

避孕植入領域的主要企業正致力於透過配方創新、提升易用性以及提供全生命週期支援服務來增強產品差異化優勢。這些企業優先考慮產生可靠的臨床證據並參與指南制定，以增強臨床可信度，並為醫保報銷談判奠定基礎。與醫療服務提供者網路和專業協會的策略合作正在拓展培訓舉措，並支持收集真實世界結果數據，最終有助於推動產品的普及應用。

為製造商、醫療服務提供者和支付方提供切實可行的策略，以加強證據支持、拓展通路、增強供應鏈韌性並改善醫療服務可及性。

產業領導者應將臨床證據的產生與有針對性的醫護人員教育計畫結合，以促進信任和合理使用。對實用性試驗和上市後監測的投入能夠加強支持指南發布和醫保支付方討論的證據基礎，而結構化的植入和取出培訓項目則能提高醫護人員的信心並改善患者預後。這些措施能夠減少診療過程中的摩擦，並支持永續的服務提供。

採用嚴謹的混合調查方法，結合相關人員訪談、臨床指引綜合和供應鏈圖譜分析，得出檢驗的營運洞察。

本研究基於檢驗基礎，採用混合方法，結合對臨床醫生、採購主管和支付方代表的定性訪談，以及對臨床指南、監管文件和同行評審文獻的系統性回顧。供應鏈圖譜和分銷管道分析納入了製造商資訊披露的資訊、競標資訊以及機構買家可觀察的庫存管理實踐，從而能夠深入了解物流限制因素和營運解決方案。

這項研究是一項實用性綜合研究，強調臨床療效必須與營運準備和商業性協調相結合，才能確保持續的可及性和影響力。

本概要中概述的融合趨勢表明，未來避孕植入將融入多元化的醫療服務路徑，並以更強力的臨床證據、數位互動工具和適應性分銷模式為支持。營運韌性、臨床醫生培訓以及與支付方優先事項的契合度將決定創新能否帶來持續的可及性和更好的患者療效。簡而言之，僅靠技術性能並不能保證推廣應用；實施機制和商業性契合度同樣至關重要。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 婦科避孕植入市場（依產品分類）

  • 依托孕烯植入
  • levonorgestrel植入

9. 依最終使用者分類的婦科避孕植入市場

  • 診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專業醫療中心

10. 婦科避孕植入市場（依通路分類）

  • 離線
  • 線上

11. 各地區婦科避孕植入市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

12. 婦科避孕植入市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各國婦科避孕植入市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

14. 美國婦科避孕植入市場

第15章 中國婦科避孕植入市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actavis plc
  • Agile Therapeutics, Inc.
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Evofem Biosciences, Inc.
  • Gilead Sciences, Inc.
  • HRA Pharma
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Warner Chilcott plc
Product Code: MRR-7B550E008DCB

The Gynecological Contraceptive Implant Market was valued at USD 450.94 million in 2025 and is projected to grow to USD 475.52 million in 2026, with a CAGR of 5.52%, reaching USD 657.19 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 450.94 million
Estimated Year [2026] USD 475.52 million
Forecast Year [2032] USD 657.19 million
CAGR (%) 5.52%

An integrated orientation to contraceptive implant clinical relevance, stakeholder responsibilities, and operational implications across care pathways and patient journeys

Contraceptive implants have emerged as a durable, clinician-administered option within the broader spectrum of reproductive health tools, delivering sustained hormone release and predictable contraceptive efficacy. These devices increasingly intersect with clinical pathways spanning family planning clinics, general practice, hospitals, and specialized youth and women's health centers, creating a set of operational and clinical considerations that extend beyond product performance to encompass training, inventory management, and patient counseling.

Clinicians and health systems are balancing clinical benefits against logistics such as insertion and removal capacity, follow-up protocols, and reimbursement models. Concurrently, patients evaluate implants in the context of contraceptive choice, side effect profiles, and long-term reproductive planning. Consequently, stakeholders must interpret clinical trial data alongside real-world evidence, payer practices, and shifting patient preferences to inform procurement, policy, and service delivery.

This summary synthesizes critical developments shaping contraceptive implant adoption, captures structural market shifts, and highlights operational levers that can be applied by manufacturers, providers, payers, and policy makers. It is intended to support strategic decision-making by presenting an integrated view of product types, care settings, distribution channels, regulatory pressures, and demographic patterns that influence access and utilization.

A concise synthesis of how clinical innovation, digital care delivery, and policy adjustments are jointly redefining product adoption pathways and service economics

The landscape for contraceptive implants is being reshaped by converging clinical, technological, and policy shifts that redefine product development and service delivery. Advances in device design and hormone formulations are paired with emerging evidence on extended-duration use and return-to-fertility profiles, prompting clinicians and guideline bodies to reassess counseling frameworks and insertion protocols. As a result, clinical practice is moving toward more individualized contraceptive planning that accounts for patient lifecycle considerations and coexisting medical conditions.

Digital health and telemedicine are exerting an outsized influence on patient engagement and follow-up care. Remote counseling, appointment triage, and digital adherence supports are smoothing access barriers while enabling more efficient clinic workflows. At the same time, distribution models are diversifying: pharmacy-based services and online information platforms are expanding points of access and shifting the locus of patient education. Consequently, manufacturers and providers are increasingly investing in digital materials, training platforms, and partnerships that bridge clinical and community settings.

Policy and regulatory changes are also catalyzing transformation. Greater emphasis on reproductive health equity and updated reimbursement codes in several jurisdictions are altering service economics, while supply chain resilience investments are prompting re-evaluation of sourcing and inventory strategies. Taken together, these shifts demand integrated commercial and clinical responses that align product portfolios, go-to-market approaches, and provider education initiatives with emerging patterns of care and patient expectations.

A clear-eyed assessment of how 2025 tariff measures have reshaped sourcing, procurement, and service delivery costs across implant supply chains

Tariff policy enacted in the United States in 2025 has introduced additional import considerations for components and finished contraceptive implants, creating pervasive effects across manufacturing, distribution, and procurement channels. These duties have raised landed costs for products and inputs sourced from affected jurisdictions, prompting manufacturers to evaluate sourcing alternatives and to reassess pricing strategies. In turn, procurement teams at hospitals, clinics, and specialty centers have faced tighter negotiations and increased scrutiny of total cost of ownership for implant programs.

Supply chain adaptation has been a consistent response. Manufacturers with diversified supplier networks accelerated qualification of secondary suppliers and increased regional warehousing to mitigate duty exposure and reduce lead-time risk. Meanwhile, some buyers adopted longer-term contracting approaches to stabilize supply and manage cost volatility. These operational responses have implications for inventory turnover, capital tied up in stock, and the agility of clinical services to respond to demand fluctuations.

At the clinical interface, increased input costs can affect service delivery decisions; healthcare organizations have had to reconcile budgetary pressures with commitments to access and quality. In some instances, administrators have prioritized training and retention of insertion-capable staff to preserve service volume despite cost headwinds. Importantly, the cumulative impact of tariff-related cost shifts has heightened the incentive for stakeholders to pursue value-based purchasing, local manufacturing partnerships, and policy engagement to reduce trade-related friction and protect access to long-acting reversible contraceptive options.

A nuanced segmentation-driven narrative that connects product chemistries, care settings, distribution pathways, and age-based patient priorities to operational implications

Insights drawn from product segmentation reveal distinct clinical and commercial dynamics for the two principal implant chemistries. Etonogestrel implants are often positioned for long-acting contraception with established provider familiarity and structured follow-up protocols, while levonorgestrel implants are frequently considered when alternative hormonal profiles or cost-sensitive procurement objectives apply. These product distinctions influence clinician training needs, counseling narratives, and inventory planning across care settings.

When viewed through the lens of end users, clinics, hospitals, and specialty centers present different operational realities. Family planning and general clinics prioritize high-throughput counseling and efficient same-day insertion workflows; hospitals, whether private or public, focus on integrated perioperative and outpatient services where implants may be part of broader reproductive health offerings; and specialty centers such as women's health and youth-focused clinics tailor services to specific demographic or clinical needs, emphasizing privacy, continuity of care, and age-appropriate counseling. Each end-user archetype drives particular purchasing behaviors and support requirements from manufacturers.

Distribution channel segmentation further refines access pathways. Hospital pharmacies serve institutional inventory and clinician-administered services, retail pharmacies-both chain and independent-support community access often linked to prescription fulfillment and counseling touchpoints, and online pharmacies operating via manufacturer websites or third-party platforms facilitate broader reach and informational resources that can supplement clinical engagement. Finally, demographic segmentation by age groups from mid-adolescence through the early 40s highlights differing contraceptive priorities, adherence considerations, and counseling emphases, with younger cohorts often prioritizing reversible and low-maintenance options while older cohorts may weigh long-term planning and return-to-fertility timelines.

A comparative regional analysis explaining how regulatory diversity, health system structure, and local access priorities influence implant delivery across global geographies

Regional dynamics shape regulatory processes, payer interactions, and service delivery architectures in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated health systems and large private provider networks drive concentrated procurement cycles and centralized training programs, while diverse public health initiatives in the region emphasize access expansion and task-sharing to enhance contraceptive availability.

Across Europe, the Middle East & Africa, heterogeneous regulatory regimes and variable infrastructure capacity create a mosaic of access models. High-income European markets emphasize reimbursement complexity and clinician credentialing for insertion, whereas many countries within the broader Middle East and Africa region prioritize capacity building, decentralized service delivery, and donor-supported programs to extend reach into underserved populations. These contrasts influence manufacturer go-to-market strategies and clinical training investments.

Asia-Pacific markets combine rapid adoption pathways in urban centers with ongoing access challenges in rural areas. Regulatory timelines and local manufacturing incentives can accelerate product registration and distribution in some economies, while in others, complex import procedures and variable payer coverage require adaptive distribution models. Across regions, stakeholders increasingly weigh regional partnerships, localized education programs, and supply chain resilience initiatives to reconcile global production footprints with local access imperatives.

Strategic corporate responses and competitive positioning that prioritize clinical evidence, channel diversification, and resilient supply operations to drive adoption

Leading firms in the contraceptive implant space are concentrating efforts on enhancing product differentiation through formulation innovation, ease-of-use improvements, and lifecycle support services. Companies prioritize robust clinical evidence generation and guideline engagement to reinforce clinical confidence and inform reimbursement discussions. Strategic collaboration with provider networks and professional societies amplifies training initiatives and supports real-world outcomes data collection that, in turn, supports adoption.

Commercial strategies emphasize channel diversification and patient-centered value propositions. Firms are expanding beyond traditional provider-focused sales models to incorporate digital education, co-pay support, and enhanced warranty or replacement programs. Supply chain strategies have become more resilient through supplier qualification, localized assembly, and expanded safety stock holdings, balancing cost efficiency against service continuity.

Competitive dynamics also reflect a tightening regulatory environment and higher barriers for new entrants, prompting incumbents to pursue incremental innovation, strategic alliances, or targeted acquisitions to fill portfolio gaps. Across the board, successful companies deploy cross-functional coordination between clinical affairs, regulatory, supply chain, and commercial teams to accelerate field adoption while maintaining compliance and quality standards.

Actionable strategies for manufacturers, providers, and payers to strengthen evidence, diversify channels, and build supply resilience while improving access

Industry leaders should align clinical evidence generation with targeted provider education programs to accelerate trust and appropriate utilization. Investing in pragmatic trials and post-market surveillance enhances the evidence base that supports guideline inclusion and payer discussions, while structured training programs for insertion and removal improve provider confidence and patient outcomes. These measures reduce friction at the point of care and support sustained service delivery.

Diversifying distribution options and reinforcing supply chain resilience will limit exposure to trade and logistical disruptions. Establishing secondary sources for critical components, regional warehousing, and flexible contracting with key buyers can reduce lead-time variability and price pressure. Simultaneously, manufacturers and suppliers should strengthen partnerships with pharmacy networks and digital platforms to expand access while ensuring clinical oversight and counseling resources are available.

Finally, aligning commercial models with value-based procurement principles will help reconcile cost pressures with access goals. Offering bundled training, outcome monitoring, and outcome-based contracting mechanisms where feasible creates shared incentives for quality care. Leaders should also proactively engage with policymakers and payer groups to articulate the population health benefits of long-acting contraceptive options and to inform reimbursement frameworks that support equitable access.

A rigorous mixed-methods methodology combining stakeholder interviews, clinical guideline synthesis, and supply chain mapping to produce validated operational insights

This research draws upon a mixed-methods approach combining primary qualitative interviews with clinicians, procurement leaders, and payer representatives, together with systematic review of clinical guidelines, regulatory filings, and peer-reviewed literature to construct a validated evidence base. Supply chain mapping and distribution channel analysis were informed by manufacturer disclosures, procurement tenders, and observable inventory practices at institutional buyers, enabling a pragmatic view of logistical constraints and operational responses.

Data triangulation was applied to reconcile differences between clinical efficacy data and real-world utilization patterns, integrating insights from professional society recommendations, training curricula, and outcome registries. Stakeholder interviews were structured to explore adoption barriers, reimbursement dynamics, and clinical workflow impacts, while methodological safeguards included multiple coder validation, source cross-referencing, and transparency about data limitations.

Limitations include variability in reporting standards across jurisdictions and the evolving nature of tariff and trade policy. To mitigate these, the analysis emphasizes structural drivers and demonstrable operational responses rather than speculative projections. The methodology supports robust, actionable conclusions by emphasizing reproducibility, stakeholder validation, and clear linkage between evidence and recommended actions.

A pragmatic synthesis emphasizing that clinical efficacy must be paired with operational readiness and commercial alignment to secure lasting access and impact

The convergent trends outlined in this summary point to a future where contraceptive implants are integrated into diversified care pathways supported by enhanced clinical evidence, digital engagement tools, and adaptive distribution models. Operational resilience, clinician training, and alignment with payer priorities will determine whether innovations translate into sustained access and improved patient outcomes. In short, technical performance alone will not assure adoption; implementation mechanics and commercial alignment are equally pivotal.

Stakeholders that invest in coordinated evidence generation, provider enablement, and supply chain flexibility will be best positioned to navigate policy shifts and cost pressures while preserving access. By focusing on pragmatic interventions-such as targeted training, secondary sourcing, and collaboration with community pharmacies-organizations can reduce friction and expand equitable reach. The combined emphasis on clinical rigor and operational practicality offers a clear path to strengthening the role of implants within comprehensive reproductive health services.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gynecological Contraceptive Implant Market, by Product

  • 8.1. Etonogestrel Implant
  • 8.2. Levonorgestrel Implant

9. Gynecological Contraceptive Implant Market, by End User

  • 9.1. Clinic
  • 9.2. Hospital
    • 9.2.1. Private Hospital
    • 9.2.2. Public Hospital
  • 9.3. Specialty Center

10. Gynecological Contraceptive Implant Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Gynecological Contraceptive Implant Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Gynecological Contraceptive Implant Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Gynecological Contraceptive Implant Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Gynecological Contraceptive Implant Market

15. China Gynecological Contraceptive Implant Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Actavis plc
  • 16.6. Agile Therapeutics, Inc.
  • 16.7. Allergan plc
  • 16.8. Amgen Inc.
  • 16.9. AstraZeneca PLC
  • 16.10. Bayer AG
  • 16.11. Bristol-Myers Squibb Company
  • 16.12. Eli Lilly and Company
  • 16.13. Evofem Biosciences, Inc.
  • 16.14. Gilead Sciences, Inc.
  • 16.15. HRA Pharma
  • 16.16. Johnson & Johnson
  • 16.17. Merck & Co., Inc.
  • 16.18. Mylan N.V.
  • 16.19. Novartis AG
  • 16.20. Novo Nordisk A/S
  • 16.21. Pfizer Inc.
  • 16.22. Roche Holding AG
  • 16.23. Sanofi S.A.
  • 16.24. Sun Pharmaceutical Industries Ltd.
  • 16.25. Takeda Pharmaceutical Company Limited
  • 16.26. Teva Pharmaceutical Industries Ltd.
  • 16.27. Warner Chilcott plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ETONOGESTREL IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ETONOGESTREL IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ETONOGESTREL IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY LEVONORGESTREL IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY LEVONORGESTREL IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY LEVONORGESTREL IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. AMERICAS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 35. AMERICAS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. NORTH AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASEAN GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 77. ASEAN GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GCC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GCC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 82. GCC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GCC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 84. GCC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPEAN UNION GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPEAN UNION GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPEAN UNION GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. BRICS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. BRICS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 92. BRICS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. G7 GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. G7 GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. G7 GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. G7 GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 99. G7 GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NATO GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NATO GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 102. NATO GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NATO GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 104. NATO GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)